<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1145">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541485</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1516101_Phillipphines</org_study_id>
    <nct_id>NCT04541485</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)</brief_title>
  <official_title>Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and tolerability of single doses of DWRX2003 in
      COVID-19 patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 6, 2020</start_date>
  <completion_date type="Anticipated">January 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>follow-up 42 days after dosing</time_frame>
    <description>Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to SARS-CoV-2 eradication (days) by Nasopharyngeal specimen</measure>
    <time_frame>follow-up 42 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of SARS-CoV-2 eradication by Nasopharyngeal specimen</measure>
    <time_frame>at Day 3, 7, 10 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19 Patients</condition>
  <arm_group>
    <arm_group_label>Experimental: Cohort 1 (96 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 mg/0.1 mL x 4 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 2 (288 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>72 mg/0.3 mL x 4 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 3 (480 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg/0.5 mL x 4 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 4 (672 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>168 mg/0.7 mL x 4 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 5 (960 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg/1.0 mL x 4 sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWRX2003</intervention_name>
    <description>Intramuscularly injection at pre-defined injection sites</description>
    <arm_group_label>Experimental: Cohort 1 (96 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 2 (288 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 3 (480 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 4 (672 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 5 (960 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscularly injection at pre-defined injection sites</description>
    <arm_group_label>Experimental: Cohort 1 (96 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 2 (288 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 3 (480 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 4 (672 mg)</arm_group_label>
    <arm_group_label>Experimental: Cohort 5 (960 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18 and 65 years of age, inclusive at time of signing the ICF.

          2. Subjects with low to moderate risk defined as NEWS COVID-19 infection as confirmed by
             Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) assay 72 hours prior to
             clinical trial enrollment.

        Exclusion Criteria:

          1. History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance, unless approved by the Investigator (or designee). Please
             note patients with allergies which can be managed without treatment can be included
             based on the decision of the Investigator (or designee).

          2. Significant history, clinical manifestation of any medical disorder or any comorbid
             conditions which in the opinion of the investigator may interfere with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

